Neurogene (NGNE) Assets (2013 - 2026)
Neurogene's (NGNE) quarterly Assets came in at $263.1 million in Q1 2026, down 16.54% YoY from $315.3 million in Q1 2025, and down 8.82% on a QoQ basis from $288.6 million in Q4 2025.
Neurogene (NGNE) Assets (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Assets data on file, last reported at $263.1 million in Q1 2026.
- Quarterly Assets fell 16.54% year-over-year to $263.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $263.1 million (down 16.54% YoY) and the FY2025 annual result came in at $288.6 million, down 14.04% from the prior year.
- Assets fell to $263.1 million in Q1 2026, from $288.6 million in the prior quarter.
- In the past five years, Assets ranged from a high of $335.7 million in Q4 2024 to a low of $89.6 million in Q3 2023.
- A 5-year average of $197.3 million and a median of $179.8 million in 2024 frame the typical range for Assets.
- The widest YoY moves for Assets: up 103.7% in 2023, down 33.98% in 2023.
- Tracing NGNE's Assets over 5 years: stood at $109.3 million in 2022, then jumped by 103.7% to $222.6 million in 2023, then soared by 50.84% to $335.7 million in 2024, then slipped by 14.04% to $288.6 million in 2025, then dropped by 8.82% to $263.1 million in 2026.
- The last three Assets figures came in at $263.1 million (Q1 2026), $288.6 million (Q4 2025), and $287.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 244.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 244.36 Mn |
| Mar 31, 2026 | 263.14 Mn |
| Dec 31, 2025 | 288.60 Mn |
| Sep 30, 2025 | 287.83 Mn |
| Jun 30, 2025 | 297.32 Mn |
| Mar 31, 2025 | 315.30 Mn |
| Dec 31, 2024 | 335.73 Mn |
| Sep 30, 2024 | 164.12 Mn |
| Jun 30, 2024 | 179.82 Mn |
| Mar 31, 2024 | 195.35 Mn |
| Dec 31, 2023 | 222.57 Mn |
| Sep 30, 2023 | 89.59 Mn |
| Jun 30, 2023 | 94.01 Mn |
| Mar 31, 2023 | 98.46 Mn |
| Dec 31, 2022 | 109.27 Mn |
| Sep 30, 2022 | 126.58 Mn |
| Jun 30, 2022 | 137.02 Mn |
| Mar 31, 2022 | 149.13 Mn |
| Dec 31, 2021 | 163.26 Mn |
| Sep 30, 2021 | 175.93 Mn |